RU2569302C2 - Соединения и фармацевтические комбинации для лечения нейродегенеративных и ишемических болезней мозга - Google Patents

Соединения и фармацевтические комбинации для лечения нейродегенеративных и ишемических болезней мозга Download PDF

Info

Publication number
RU2569302C2
RU2569302C2 RU2014103246/04A RU2014103246A RU2569302C2 RU 2569302 C2 RU2569302 C2 RU 2569302C2 RU 2014103246/04 A RU2014103246/04 A RU 2014103246/04A RU 2014103246 A RU2014103246 A RU 2014103246A RU 2569302 C2 RU2569302 C2 RU 2569302C2
Authority
RU
Russia
Prior art keywords
pcb
ifn
seq
peptide
weight
Prior art date
Application number
RU2014103246/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2014103246A (ru
Inventor
РОЛЬ Хиселье ПЕНТОН
АРСУАГА Алексей ЛЛОПИС
ПРИДА Хавьер МАРИН
АРИАС Эдуардо ПЕНТОН
ХИМЕНЕС Эфраин РОДРИГЕС
ЛАСА Алексис МУСАКЧИО
ПЕРЕС Владимир Армандо БЕСАДА
АНДРЕУ Хилберто Ласаро ПАРДО
ЛОПЕС Луис Хавьер ГОНСАЛЕС
ФУЭНТЕС Нанси ПАВОН
Ньето Херардо Энрике Гильен
САУРА Педро Антонио ЛОПЕС
Original Assignee
Сентро Де Инхеньерия Хенетика И Биотекнолохия
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентро Де Инхеньерия Хенетика И Биотекнолохия filed Critical Сентро Де Инхеньерия Хенетика И Биотекнолохия
Publication of RU2014103246A publication Critical patent/RU2014103246A/ru
Application granted granted Critical
Publication of RU2569302C2 publication Critical patent/RU2569302C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
RU2014103246/04A 2011-07-01 2012-06-29 Соединения и фармацевтические комбинации для лечения нейродегенеративных и ишемических болезней мозга RU2569302C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2011/0146 2011-07-01
CU2011000146A CU23963B1 (es) 2011-07-01 2011-07-01 Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
PCT/CU2012/000003 WO2013004203A1 (es) 2011-07-01 2012-06-29 Compuestos y combinaciones farmacéuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas

Publications (2)

Publication Number Publication Date
RU2014103246A RU2014103246A (ru) 2015-08-10
RU2569302C2 true RU2569302C2 (ru) 2015-11-20

Family

ID=46614264

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014103246/04A RU2569302C2 (ru) 2011-07-01 2012-06-29 Соединения и фармацевтические комбинации для лечения нейродегенеративных и ишемических болезней мозга

Country Status (18)

Country Link
US (2) US9518085B2 (enExample)
EP (1) EP2733149B9 (enExample)
JP (1) JP6023803B2 (enExample)
KR (1) KR101987978B1 (enExample)
CN (1) CN103649106B (enExample)
AR (1) AR087034A1 (enExample)
AU (1) AU2012280776B2 (enExample)
BR (1) BR112013033970B1 (enExample)
CA (1) CA2838496C (enExample)
CU (1) CU23963B1 (enExample)
DK (1) DK2733149T3 (enExample)
ES (1) ES2601887T3 (enExample)
IN (1) IN2014CN00510A (enExample)
MX (1) MX345534B (enExample)
RU (1) RU2569302C2 (enExample)
SI (1) SI2733149T1 (enExample)
WO (1) WO2013004203A1 (enExample)
ZA (1) ZA201309554B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2613765C1 (ru) * 2016-01-26 2017-03-21 Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" Способ лечения спиноцеребеллярной атаксии

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3013355B1 (en) * 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 for use in treating alzheimer disease and related disorders
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN108752445B (zh) * 2018-06-20 2021-04-30 广东药科大学 一种螺旋藻蛋白的制备工艺及其神经保护用途
KR102152407B1 (ko) * 2019-02-26 2020-09-07 (주)나우코스 스피루리나에서 유래한 파이코시아노블린 및 이의 유도체를 유효성분으로 포함하는 화장료 조성물
KR20210091664A (ko) 2020-01-14 2021-07-22 경북대학교 산학협력단 중간엽 줄기세포 유래 단백질을 포함하는 소뇌성운동실조증의 치료 예후를 예측하기 위한 바이오마커, 및 이를 이용한 소뇌성운동실조증의 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025965B1 (en) * 2003-02-12 2006-04-11 Pharma Chemie, Inc. Method of use and dosage composition of bluegreen algae extract for inflammation in animals
RU2008121248A (ru) * 2005-10-28 2009-12-10 Сентро Де Инхеньерия Хенетика И Биотекнолохия (Cu) Интерферон альфа и с-фикоцианин для лечения аутоиммунных заболеваний, аллергии и рака

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2004084933A1 (en) * 2003-03-28 2004-10-07 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
RU2441663C2 (ru) * 2006-06-27 2012-02-10 Нутратек С.Р.Л. Препарат aphanizomenon flos aquae, экстракты и очищенные компоненты экстрактов для лечения неврологических, нейродегенеративных и аффективных расстройств
CA2668757C (en) * 2006-11-13 2016-08-23 Mark Fredrick Mccarty Composition for inhibiting nadph oxidase activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025965B1 (en) * 2003-02-12 2006-04-11 Pharma Chemie, Inc. Method of use and dosage composition of bluegreen algae extract for inflammation in animals
RU2008121248A (ru) * 2005-10-28 2009-12-10 Сентро Де Инхеньерия Хенетика И Биотекнолохия (Cu) Интерферон альфа и с-фикоцианин для лечения аутоиммунных заболеваний, аллергии и рака

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Arciero-DM et al.: "In vitro attachment of bilins to apophycocyanin", Journal of Biological Chemistry, 1988, vol. 263, no. 34, 1988, pages 18343-18349. *
Schoenleber-RW et al.: "Bilin attachment sites in the alpha and beta subunits of B-Phycoerythrin", Journal of Biological Chemistry, 1984, vol. 259, no. 9. LAGARIAS J C ET AL: "CHROMOPEPTIDES FROM C-PHYCOCYANIN. STRUCTURE AND LINKAGE OF A PHYCOCYANOBILIN BOUND TO THE BETA SUBUNIT", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1979, vol. 101, no. 17. ROMAY CH ET AL: "C-phycocyanin: A biliprotein with antioxidant, anti-inflammatory and neuroprotective effects", CURRENT PROTEIN AND PEPTIDE SCIENCE, 2003, vol. 4, no. 3, pages 207-216. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2613765C1 (ru) * 2016-01-26 2017-03-21 Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" Способ лечения спиноцеребеллярной атаксии

Also Published As

Publication number Publication date
ES2601887T3 (es) 2017-02-16
CN103649106B (zh) 2016-01-20
MX345534B (es) 2017-02-03
US20140356319A1 (en) 2014-12-04
EP2733149B9 (en) 2019-05-15
KR20140078601A (ko) 2014-06-25
SI2733149T1 (sl) 2017-01-31
BR112013033970B1 (pt) 2022-10-18
CU20110146A7 (es) 2013-02-26
DK2733149T3 (en) 2016-11-28
RU2014103246A (ru) 2015-08-10
EP2733149A1 (en) 2014-05-21
IN2014CN00510A (enExample) 2015-04-03
BR112013033970A2 (pt) 2017-02-14
AR087034A1 (es) 2014-02-05
WO2013004203A1 (es) 2013-01-10
US20170119733A1 (en) 2017-05-04
JP6023803B2 (ja) 2016-11-09
AU2012280776B2 (en) 2016-07-14
CU23963B1 (es) 2013-12-11
JP2014520764A (ja) 2014-08-25
ZA201309554B (en) 2014-08-27
KR101987978B1 (ko) 2019-06-11
AU2012280776A1 (en) 2014-01-23
CA2838496A1 (en) 2013-01-10
MX2013015206A (es) 2014-02-20
US9518085B2 (en) 2016-12-13
CA2838496C (en) 2020-01-07
CN103649106A (zh) 2014-03-19
EP2733149B1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
RU2569302C2 (ru) Соединения и фармацевтические комбинации для лечения нейродегенеративных и ишемических болезней мозга
KR102345605B1 (ko) 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
JP2018506506A (ja) 神経変性障害
KR20050115279A (ko) 알츠하이머병과 치매 질환의 치료를 위하여 단독으로 또는다른 치료제와 공동으로 이용되는 ｉｆｎ-베타
AU2010203446B2 (en) Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
US20150133388A1 (en) Acetylated crystallin polypeptides and mimetics thereof as therapeutic agents
US10400009B2 (en) β-sheet breaker peptide used for preventing and/or treating alzheimer's disease
EP3233102B1 (en) Use of an antimicrobial peptide to induce cell death in breast cancer
AU2019202876B2 (en) Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders
KR20160053027A (ko) ｈＲｈｅｂ를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물
CN121311236A (zh) 一种治疗颅脑损伤的药物及其应用
CN120939206A (zh) Metrnl蛋白与氯吡格雷联合治疗血栓的药物组合物及其应用
JP5439007B2 (ja) 血管内皮細胞増殖因子阻害剤及び抗癌剤
JPH05213767A (ja) 脳神経疾患治療剤
WO2000024414A1 (fr) Agents preventifs/curatifs pour les maladies du foie